Compare FTEK & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTEK | CTSO |
|---|---|---|
| Founded | 1987 | 1997 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.0M | 45.9M |
| IPO Year | N/A | N/A |
| Metric | FTEK | CTSO |
|---|---|---|
| Price | $1.37 | $0.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $5.38 |
| AVG Volume (30 Days) | ★ 178.6K | 79.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.16 | $7.29 |
| Revenue Next Year | $21.36 | $8.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.60 |
| 52 Week High | $3.65 | $1.39 |
| Indicator | FTEK | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 43.83 |
| Support Level | $1.25 | $0.62 |
| Resistance Level | $1.48 | $0.67 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 56.52 | 13.55 |
Fuel Tech Inc is an technology provider of boiler optimization, efficiency improvement, and air pollution reduction to utility and industrial customers. The company operates in two segments, Air Pollution Control and Fuel Chem. The Air Pollution Control technology segment includes technologies to reduce NOx emissions in flue gas from boilers, incinerators, furnaces and other stationary combustion sources. The Fuel Chem technology segment uses chemical processes in combination with Computational Fluid Dynamics and Chemical Kinetics Modeling boiler modeling for the control of slagging, fouling, corrosion, opacity and other sulfur trioxide-related issues in furnaces and boilers through the addition of chemicals into the furnace using TIFI Targeted In-Furnace Injection technology.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.